Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

Dow Jones01-01 06:05

By Katherine Hamilton

Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration.

The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year.

The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration.

Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for.

In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 31, 2025 17:05 ET (22:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600704580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-01 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600704580","market":"other","top_or_hot":-1,"title":"Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. \n</p>\n<p>\n  The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year. \n</p>\n<p>\n  The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration. \n</p>\n<p>\n  Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for. \n</p>\n<p>\n  In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 31, 2025 17:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-01 06:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. \n</p>\n<p>\n  The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year. \n</p>\n<p>\n  The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration. \n</p>\n<p>\n  Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for. \n</p>\n<p>\n  In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 31, 2025 17:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2600704580","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600704580","pubTimestamp":1767218700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration.The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year.The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration.Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for.In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OTLK":"Outlook Therapeutics, Inc.","BK4007":"制药","BK4539":"次新股","LENZ":"Therapeutics"},"translate_title":"FDA再次拒绝黄斑变性药物后Outlook Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTLK":0.9,"LENZ":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. \n\n\n  The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year. \n\n\n  The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration. \n\n\n  Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for. \n\n\n  In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 31, 2025 17:05 ET (22:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600704580","isCrawlerRequest":true}